Aibin J. Liang

No. 389 Xincun Road
Xincun, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Correction: Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting.

Correction: Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting.

Journal: Experimental hematology & oncology

Published: April 06, 2026

Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting.

Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting.

Journal: Experimental hematology & oncology

Published: December 17, 2025

Near-infrared orthogonal excitation lanthanide theranostic nanoplatform for NIR-II-L imaging-guided photodynamic therapy via synergistical pyroptosis and apoptosis pathway.

Near-infrared orthogonal excitation lanthanide theranostic nanoplatform for NIR-II-L imaging-guided photodynamic therapy via synergistical pyroptosis and apoptosis pathway.

Journal: Biomaterials

Published: October 14, 2025

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia.

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia.

Journal: Journal of hematology & oncology

Published: September 02, 2025

Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed/refractory NHL: a propensity score matching cohort study.

Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed/refractory NHL: a propensity score matching cohort study.

Journal: Journal of translational medicine

Published: September 02, 2025

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.

Journal: Nature cancer

Published: July 03, 2025

Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers.

Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers.

Journal: The Journal of biological chemistry

Published: May 09, 2025

Germline mutations in B-cell non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) and patient outcomes.

Germline mutations in B-cell non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) and patient outcomes.

Journal: Seminars in oncology

Published: April 15, 2025

A broadly neutralizing antibody recognizes a unique epitope with a signature motif common across coronaviruses.

A broadly neutralizing antibody recognizes a unique epitope with a signature motif common across coronaviruses.

Journal: Nature communications

Published: January 30, 2025

Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study.

Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study.

Journal: Molecular biomedicine

Published: January 21, 2025

Benchmarking algorithms for generalizable single-cell perturbation response prediction.

Benchmarking algorithms for generalizable single-cell perturbation response prediction.

Journal: Nature methods

Published: January 20, 2025

Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.

Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.

Journal: Blood advances

Published: January 02, 2025

Showing 1-12 of 61

Last Updated: 09/26/2026